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Abstract
We present evidence that variations in cyclin D1 levels through the cell cycle are essential for
continuing proliferation. Cyclin D1 levels must be high during G1 phase for a cell to initiate DNA
synthesis, but then must be suppressed to low levels during S phase to allow for efficient DNA
synthesis. This suppression during S phase is apparently regulated by cell cycle position alone and
occurs automatically during each cell cycle. If the cell is to continue proliferating, cyclin D1 levels
must be induced once again during G2 phase. This induction depends upon the activity of
proliferative signaling molecules, and ensures that the extracellular environment continues to be
conducive for growth. We propose that the suppression of cyclin D1 levels during each S phase
ensures that the subsequent induction during G2 phase, and the resulting commitment to
continuing proliferation, is closely linked to the cellular growth environment.
Background
Cyclin D1 plays a central role in the regulation of prolifer-
ation, linking the extracellular signaling environment to
cell cycle progression [1]. The expression level of cyclin
D1 is highly responsive to the action of proliferative sig-
nals including growth factor receptors, Ras, and their
downstream effectors. Regulation in expression level
involves a variety of mechanisms including production,
stability and utilization of cyclin D1 mRNA; as well as
protein stability, localization, and association. Its expres-
sion increases upon stimulation of quiescent cells to enter
the cell cycle, while it has been proposed to shuttle in and
out of the nucleus through the cell cycle of actively cycling
cells [2]. Once the expression level of cyclin D1 is deter-
mined as the sum result of the cellular signaling environ-
ment, it binds cyclin dependent kinase 4 or 6 (CDK4/6)
to form an active kinase for the retinoblastoma protein
(Rb). The growth inhibitory action of Rb is neutralized
following phosphorylation by cyclin D1/CDK4, to allow
E2F transcription factors to promote the transcription of
genes required for cell cycle progression [3]. Cell cycle
progression ceases following neutralization of cyclin D1
by microinjected antibodies in many cultured cells [4,5],
even though knockout studies indicate that many of its
functions can be performed by other cyclins during devel-
opment [6-8].
Cyclin D1 levels vary through the cell cycle
The central role of cyclin D1 in promoting entry into the
cell cycle suggests it should also be important in regulat-
ing cell cycle progression once it has initiated, although
this aspect of its action has been poorly understood due to
the difficulty of studying cells that are actively cycling. In
order to study the function of cyclin D1 in cells actively
progressing through the cell cycle, we developed a quanti-
tative image analysis technique for protein quantitation in
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individual cells. Rather than attempt to force all cells into
a single cell cycle position, this approach allowed the
identification of the cell cycle position of individual cells
within an asynchronous culture. An asynchronous culture
was pulsed with BrdU and fixed, then the BrdU, DNA, and
cyclin D1 were stained with fluorescent labels. Accurate
quantitation allowed the determination of the level of
each of these markers within each individual cell. Cell
cycle position was determined based upon DNA content
and BrdU staining. Cyclin D1 expression could then be
quantitated for cells in all cell cycle periods simultane-
ously (Fig. 1). Importantly, cyclin D1-associated fluores-
cence in stained cells was shown to be directly
proportional to total cyclin D1 protein as judged by west-
ern analysis in synchronized cultures [9]. Because the
technique relied upon microscopic examination of mon-
olayer cells, it was possible to quantitate the levels of
nuclear antigens with a high degree of accuracy as indi-
cated by the detailed profile of the BrdU stain vs. DNA
content (Fig. 1, top). It is also possible to manipulate indi-
vidual cells with microinjection techniques prior to anal-
ysis. With this approach we observed high levels of cyclin
D1 in G1 and G2 phase cells. Cells in S phase, on the other
hand, uniformly contained low levels of cyclin D1 (Fig. 1
bottom) [9]. This profile was observed in all normal cells
in monolayer culture studied to date, including fibrob-
lasts and epithelial cells. The results were observed with a
variety of different antibodies (Fig. 2). Moreover, the
reduction in total cyclin D1 protein content during S
phase has been observed by western analyses of synchro-
nized cultures, and in stained sections of normal tissues.
Based upon the accumulated evidence there is little reason
to doubt that cyclin D1 levels in actively cycling cells
increase during G2 phase, are maintained through mitosis
and G1 phase, and decline when DNA synthesis begins
(Fig. 3).
Our first goal was to determine how the increase in cyclin
D1 during G2 phase is regulated, and what biological role
it plays. This increase in cyclin D1 level was shown to be
absolutely dependent upon proliferative signaling and
cellular Ras activity, since it was blocked in cells deprived
of growth factors, or microinjected with neutralizing anti-
Ras antibody. Interestingly, these treatments suppressed
cyclin D1 levels in G2 phase cells several hours prior to
any observable effect upon cyclin D1 levels during G1
phase [9]. Cyclin D1 levels were apparently determined by
extracellular signaling during G2 phase, and then main-
tained at a relatively uniform level until DNA synthesis
began. In direct support of this notion, when oncogenic
Ras protein was microinjected into actively cycling cells it
had effects upon cellular migration and gene activation
throughout the cell cycle, even though it was able to pro-
mote cyclin D1 accumulation only during G2 phase [10].
We conclude that proliferative signaling controls the ele-
vation of cyclin D1 levels during G2 phase (Fig. 3).
Elevation of cyclin D1 during the G2 phase 
promotes continuing proliferation
In order to understand why the elevation of cyclin D1 dur-
ing G2 phase is so important, it is necessary to consider
the results of an unrelated series of experiments. We
found that when anti-Ras antibody was microinjected
into actively cycling cells, it efficiently blocked cell cycle
progression, but only if present during G2 phase [5].
Profile of BrdU and cyclin D1 expression through the cell  cycle Figure 1
Profile of BrdU and cyclin D1 expression through the cell 
cycle. MRC5, human diploid fibroblasts, were pulsed with 
BrdU for 20 min, fixed and stained for cyclin D1 and BrdU 
with fluorescent antibodies, while DNA was stained with 
DAPI. Images of each fluorochrome were subjected to image 
analysis to quantitate the level of each fluorochrome in each 
cell. (Top) BrdU levels are plotted vs. DNA content for each 
cell; and (Bottom) cyclin D1 levels are plotted vs. DNA con-
tent. BrdU negative cells in G1 (red), or G2 (blue) phases are 
indicated by open circles; while S phase cells (black) are rep-
resented by smaller closed circles.
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Obviously, a target of Ras activity that is specifically active
during G2 phase is required to allow the cell to continue
active proliferation. As direct evidence that this Ras target
is cyclin D1, we found that when Ras activity was neutral-
ized by microinjected anti-Ras antibody, the cell could
continue proliferating into the next cell cycle so long as
cyclin D1 levels were artificially elevated [11,9]. We con-
clude that the ability of proliferative signaling to induce
cyclin D1 levels specifically during G2 serves to commit
the cell to continue active cell cycle progression. Impor-
tantly, this critical decision to continue active prolifera-
tion takes place just prior to entry into mitosis. In this
way, at the completion of mitosis the cell can immediately
be directed either to continued proliferation or entry into
quiescence, depending upon its extracellular growth envi-
ronment during the preceding G2 phase (Fig. 3). The stim-
ulation of cyclin D1 levels during G2 phase relies on the
ability of mitogen to stabilize its message, although cell
cycle-dependent changes in protein stability also play a
role in this G2 phase increase in cyclin D1 levels [12,13].
In support of this conclusion, cyclin D1 mRNA was
shown to be continuously synthesized and relatively sta-
ble until serum was removed from the culture, at which
Cyclin D1 and phospho-cyclin D1 staining patterns Figure 2
Cyclin D1 and phospho-cyclin D1 staining patterns. (A) MRC5 cells were pulsed with BrdU and stained as described in Figure 
1. Fluorescence photographs of BrdU, cyclin D1 and DNA stains for a single group of cells are presented. Separate cells stain 
for cyclin D1 and BrdU. (B) NIH3T3 cells were fixed and stained with antibodies against total cyclin D1, or cyclin D1 phospho-
rylated on Thr-286. This procedure was performed on untreated cells, or following a three hr treatment with MG132 to block 
proteasomal degradation. Fluorescence images of the same area of cells are presented, along with DAPI stained DNA. No 
accumulation of cytoplasmic cyclin D1 or phospho-cyclin D1 is apparent in any of these cells.
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time its stability was dramatically and immediately
reduced [12].
Cyclin D1 suppression during S phase ensures 
constant proliferative signaling
We postulated that cyclin D1 levels are suppressed during
S phase to ensure that proliferation continues only in cells
with a positive growth environment during the succeed-
ing G2 phase. In other words, the suppression of cyclin
D1 levels during S phase effectively erases the effects of
any signaling events from previous cell cycle periods, and
ensures that for continued proliferation the cellular envi-
ronment must be reassessed prior to the initiation of every
new cell cycle. To gain further evidence for this idea we
undertook an analysis of the mechanism by which cyclin
D1 levels are suppressed during S phase. Metabolic labe-
ling studies and quantitative image analysis demonstrated
that the decline of cyclin D1 during S phase was due to a
decrease in protein stability specifically during S phase in
actively cycling cells [13]. Further studies demonstrated
that cyclin D1 declined as the result of proteasomal degra-
dation following phosphorylation of Thr-286 [14]; since
mutants of this site maintained high cyclin D1 levels
through S phase [13,15], and accumulation of phosphor-
ylated cyclin D1 increased most rapidly in S phase cells
when proteasomal degradation was inhibited [13].
Efforts were next made to identify the kinase involved in
phosphorylation of Thr-286 as a means of studying the
molecular mechanism of cyclin D1 suppression, and
thereby its biological regulation. The critical regulatory
kinase, glycogen synthase kinase 3 (GSK3), has been
shown to phosphorylate cyclin D1 on Thr-286 in vitro,
and is postulated to regulate cyclin D1 levels and intracel-
lular distribution [16]. GSK3 is inhibited following phos-
phorylation by AKT, which is in turn activated by
phosphatidylinositol-3 kinase (PI3 kinase); a prime medi-
ator of proliferative signaling. Thus, proliferative signaling
would stabilize cyclin D1 by stimulating the PI3 kinase/
AKT pathway to phosphorylate and inactivate GSK3. The
inactive GSK3 would then be unable to phosphorylate
and promote the degradation of cyclin D1. If this were to
account for the suppression of cyclin D1 during S phase,
it would be necessary that proliferative signaling, or its
connection to GSK3, cease only during S phase.
GSK3 does not regulate cyclin D1 levels
To test this model our goal was to devise means to identify
an alteration in proliferative signaling specifically during
S phase. The possibility that such an alteration might be
observed was supported by the fact, as mentioned above,
that oncogenic Ras, while active throughout the cell cycle,
is able to promote cyclin D1 elevation only during G2
phase [10]. Moreover, we have shown that proliferative
signaling is able to suppress p27 levels throughout the cell
cycle, but that different signaling pathways lead to this
suppression during each cell cycle period [17]. Thus, it
appeared reasonable to assume that an alteration in sign-
aling activity or its targets might effect GSK3 differentially
through the cell cycle. This, however, was not observed.
The cell cycle dependent change in PI3 kinase activity was
assessed by expression of a green fluorescent protein
Diagram of cyclin D1 expression through the cell cycle Figure 3
Diagram of cyclin D1 expression through the cell cycle. The bold red line indicates the expression profile of cyclin D1 through 
the cell cycle of a normal cell. The importance of this expression pattern, along with an explanation of how the changes are 
regulated is included.
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linked to a protein (the PH domain) with the ability to
move to the membrane and bind the lipid product of PI3
kinase. PI3 kinase activity, as identified by movement of
this marker protein to the plasma membrane, was
observed only following removal and re-addition of
serum growth factors to either a quiescent or an actively
cycling culture. There was no evidence of cell cycle related
changes in PI3 kinase activity. As another mechanism to
measure activity of the PI3 kinase pathway, we studied
synchronized cultures and found no evidence for altera-
tions in AKT or GSK3 activity through the cell cycle, even
though cyclin D1 levels fell during S phase and increased
during G2 phase in these same cells. Finally, we reasoned
that if alterations in cyclin D1 levels through the cell cycle
were produced by alterations in the activity or effects of
proliferative signaling, then global inhibition of prolifera-
tive signaling would tend to eliminate the cell cycle
dependent changes in cyclin D1 levels. As noted above,
however, the removal of serum, or the inhibition of Ras
activity did not eliminate cell cycle related changes in cyc-
lin D1 levels; rather, these treatments specifically reduced
cyclin D1 levels during G2 phase without effecting G1
phase levels. Moreover, in cells transformed by oncogenic
Ras, where proliferative signaling has been shown to be
constant through the cell cycle, the decline in cyclin D1
levels during S phase is still observed. We concluded that
cell cycle related alterations in proliferative signaling are
not likely to be responsible for the suppression of cyclin
D1 during S phase (Fig. 3) [18].
The above results not only raise questions regarding the
role of GSK3 in the suppression of cyclin D1 during S
phase, they raise questions regarding the potential role of
GSK3 in the regulation of cyclin D1 levels in general. To
address this concern GSK3α and GSK3β activity were both
inhibited by a variety of chemical inhibitors, and protein
levels of both proteins were suppressed with siRNA, with-
out any observable alteration in cyclin D1 expression
characteristics. Moreover, a mutation in the site normally
phosphorylated by AKT renders the GSK3β protein consti-
tutively active. A plasmid expressing such an activated
mutant was introduced into cultured cells by microinjec-
tion. This resulted in a dramatic increase in the overall lev-
els of GSK3 activity, but once again without any alteration
in the expression level of cyclin D1 or its level of phospho-
rylation on Thr-286 in any cell cycle phase. These observa-
tions suggested that the action of GSK3 within the
fibroblast cells we were studying did not directly influence
cyclin D1 levels. To directly confirm this fact an experi-
ment was performed to demonstrate the differential
effects of GSK3 inhibition upon cyclin D1 and β-catenin
phosphorylation and degradation. β-catenin is phosphor-
ylated by GSK3 bound in a multi-protein complex. The
ability of GSK3 to phosphorylate β-catenin is inhibited by
signaling through the Wnt pathway, resulting in a
decreased rate of β-catenin phosphorylation. Thus, the
inhibition of GSK3 activity can be assessed by a decrease
in β-catenin phosphorylation. NIH3T3 cells were treated
with varying levels of LiCl, a potent and relatively specific
inhibitor of GSK3. The levels of phosphorylated β-catenin
and of phosphorylated cyclin D1 were simultaneously
analyzed in the treated cells. As expected, the levels of
phosphorylated β-catenin were reduced by the LiCl treat-
ment. Of critical importance however, the levels of phos-
phorylated cyclin D1 were not altered in these cells, even
though it was clear that GSK3 had been inhibited [18]. It
is also critical to note that there was no apparent redistri-
bution of cyclin D1 between nucleus and cytoplasm in
these treated cells (Fig. 2) [19].
We conclude that in these actively cycling cells the expres-
sion level of cyclin D1 is not regulated by, and not a phys-
iological substrate of GSK3. We initiated these studies to
understand the biological mechanism by which cyclin D1
is suppressed during S phase, as a means of understanding
its physiological significance. Our results not only elimi-
nate the involvement of GSK3, these results suggest that
proliferative signaling in general is not involved in sup-
pression of cyclin D1 during S phase. This suppression
apparently takes place automatically upon the initiation
of DNA synthesis, regardless of the signaling environment
of the cell (Fig. 3).
Biological importance of cyclin D1 expression 
through the cell cycle
The fact that proliferative signaling is not apparently
involved in the suppression of cyclin D1 during S phase
has important implications. While the critical kinase
involved is not known, it appears likely that it will be reg-
ulated not so much by the signaling environment of the
cell as by the fact that the cell has entered S phase. Thus,
the suppression of cyclin D1 during S phase appears to be
governed by cell cycle position, resulting in the suppres-
sion of cyclin D1 during each S phase. An understanding
of why cyclin D1 must be suppressed during S phase
comes from previously reported studies that indicate that
cyclin D1 has the ability to inhibit DNA synthesis by vir-
tue of its ability to bind the critical regulator of DNA syn-
thesis, PCNA [20-22]. In support of this conclusion, the
level of exogenous cyclin D1 expression was directly
linked to an increase in the length of S phase [23,18], and
of the entire cell cycle [18]. Thus, not only does the cell
automatically suppress cyclin D1 during S phase; this sup-
pression appears essential to efficient cell cycle progres-
sion. These two facts clearly support our initial proposal
that the reduction of cyclin D1 during S phase enforces the
requirement for continuing positive growth conditions. In
other words, the suppression of cyclin D1 during S phase
serves as an automatic reset to erase the effects of prolifer-
ative signaling from any previous cell cycle period, andCell Division 2006, 1:32 http://www.celldiv.com/content/1/1/32
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ensure that the cell reassess its proliferative environment
prior to committing to continued active proliferation dur-
ing G2 phase (Fig. 3).
The fact that cyclin D1 levels must be suppressed during S
phase might also limit tumor formation directly. Any
mutation or alteration resulting in high cyclin D1 levels
might promote uncontrolled passage through G1 phase
and into DNA synthesis regardless of growth conditions.
The resulting cyclin D1 levels, however, might be so high
as to block progression through S phase. Thus, for active
proliferation, it is likely that the expression of this critical
regulator of growth be within a limited expression range
[24]. The ability of alterations in cyclin D1 expression to
play a role in tumor formation, therefore, might require
alterations in the processes described above that normally
limit its permissible expression range. In support of this
contention, we have observed altered cell cycle expression
profiles in many of the tumors and tumor cell lines we
have analyzed (manuscript in preparation).
Other considerations
Because cyclin D1 suppression during S phase is appar-
ently so critical in its overall ability to regulate cell cycle
progression, it is logical to question why this suppression
is not more universally recognized. A model suggesting
the decline of cyclin D1 during S phase as the result of dis-
placement by p16Ink4 was proposed a number of years
ago [1]. In addition, cyclin D1 suppression during S phase
is supported by FACS data [25,26], along with biochemi-
cal analyses of cells separated into cell cycle positions by
elutriation [27], or synchronized in mitosis [4], or by
serum addition [28-30]. Unfortunately, cell cycle syn-
chrony is often lost following mitogen stimulation of qui-
escent cells prior to exit from S phase, so that it is difficult
to observe a biochemical fall in cyclin D1 levels in quies-
cent cells stimulated with serum. FACS analysis is compli-
cated by the fact that cyclin D1 is a rather weak, nuclear
antigen. Finally, as noted above, cyclin D1 levels do not
decline during S phase in many tumor cells, so that only
studies of normal cell types can with certainty be used to
analyze cyclin D1 expression through the cell cycle.
There is no question from the literature that cyclin D1 is
reduced in the nucleus of many cell types during S phase
[28,4], based upon fluorescence staining (Fig. 2A). This
has been explained in the past, however, as the result of
intracellular redistribution following phosphorylation by
GSK3 [31-33]. Exit of cyclin D1 from the nucleus into the
cytoplasm would potentially mask its activity by separat-
ing it from its critical substrates, thus eliminating its abil-
ity to inhibit DNA synthesis. On the other hand, if the
elimination of cyclin D1 from the cell serves as the means
to ensure the constant presence of conducive growth con-
ditions as proposed above, the simple separation from
substrates might not have the profound regulatory conse-
quences that total elimination from the cell would have.
For this reason, it is of critical importance to clearly distin-
guish between redistribution and degradation. If phos-
phorylation of cyclin D1 on Thr-286 is responsible for
nuclear export and subsequent degradation, we reasoned
that the low levels of phosphorylated cyclin D1 in normal
cells would be cytoplasmic. Moreover, if proteasomal deg-
radation is blocked and the levels of total and phosphor-
ylated cyclin D1 increase, we reasoned that a significant
proportion of the excess total cyclin D1, and the majority
of the phosphorylated cyclin D1 awaiting proteasomal
degradation would localize to the cytoplasm. To test these
possibilities, NIH3T3 cells were fixed and stained for total
cyclin D1, cyclin D1 phosphorylated on Thr-286, and for
DNA. Cells were analyzed with or without a three hr
MG132 treatment to block proteasomal activity. In all
cells tested, total cyclin D1 and that phosphorylated on
Thr-286 was localized to the nucleus (Fig. 2B). This con-
clusion was clearly apparent following proteasomal inhi-
bition, although only a small number of untreated cells
express identifiable phospho-cyclin D1. Even in these few
unreated cells, however, the increase in phospho-cyclin
D1 staining was apparently always localized to the
nucleus (although the background cytoplasmic staining
makes this conclusion uncertain, Fig. 2B). These results
are not consistent with a model in which cyclin D1 moves
to the cytoplasm to await degradation, particularly if that
degradation requires phosphorylation on Thr-286.
It is important to emphasize that the conclusion that cyc-
lin D1 or any nuclear protein has exited from the nucleus
into the cytoplasm is extremely difficult to firmly estab-
lish. If this conclusion is made on the basis of subcellular
localization following cellular disruption, the determina-
tion becomes more a matter of nuclear binding than local-
ization [26], since a protein as small as cyclin D1 might be
released from the nucleus during its purification. If the
determination of cellular localization relies simply upon
analysis of stained images as described above, the chal-
lenge becomes even greater. The cross section of the
nucleus in monolayer cells is often a small fraction of the
entire cell; and this fraction varies dramatically from one
cell to another. Moreover, the nonspecific staining of
most antibodies, including many anti-cyclin D1 antibod-
ies, is greater in the cytoplasm than the nucleus. Therefore,
it is difficult to prove that an antigen has left a small
nucleus and redistributed into a larger cytoplasm, where
variations in cell thickness and size complicate accurate
determination of background staining. Such a conclusion
would require accurate determination of background
staining for the given cell, the careful quantitation of
increases of fluorescence above that background, and a
determination of whether or not this increase could be
due to the decrease in staining in the nucleus. In our care-Cell Division 2006, 1:32 http://www.celldiv.com/content/1/1/32
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ful, quantitative analyses of this type we have found no
evidence of export form the nucleus to the cytoplasm [9].
Moreover, following introduction of green fluorescent
protein tagged cyclin D1, we have found that cytoplasmic
fluorescence is always indicative of a dramatic over expres-
sion of exogenous cyclin D1. Similar conclusions result
from staining of cells following elevated expression of
exogenous, unmodified cyclin D1. We find no evidence
for exit of cyclin D1 from the nucleus into the cytoplasm
as a cell cycle regulated event. Our studies do not in every
detail duplicate the growth conditions and cell types oth-
ers have used, but we are confident that in our cells under
the conditions described above, cyclin D1 is degraded
during S phase. This fact is supported by the biochemical
studies we and others have performed as indicated above
[13,4,27-30].
A final consideration regards the potential role of GSK3 in
the control of cell growth in general. In Drosophila PI3
kinase signaling inactivates the GSK3 analogue as in
mammalian cells. In flies engineered to have a GSK3 ana-
logue which cannot be inhibited by PI3 kinase signaling,
however, the animals grow normally; indicating that tar-
gets in addition GSK3 must be involved in the ability of
PI3 kinase to regulate cell growth [34]. Similar conclu-
sions have been reached in genetic studies of mice where
neither development, nor cell growth and proliferation
were effected by blocking the activation of either GSK3α
or GSK3β [35]. In bone growth and development, where
GSK3 activity does appear to play a role, it does so by reg-
ulating the production of a growth factor rather than by
directly regulating proliferation [36]. These data support
our observation that GSK3 does not play a major role in
cell cycle regulation in actively proliferating cells. None of
these results, however, exclude the possibility that GSK3
might play an important role in the proliferation of other
types of cells, or cells in the absence of proliferative sign-
aling.
In conclusion, the evidence indicates that cyclin D1 levels
not only regulate the initiation of cell cycle progression in
quiescent cells, but that they play a critical role in the deci-
sion of a cell to continue proliferating. This decision is
made during G2 phase when proliferative signaling
induces an increase in cyclin D1 levels. The apparently
automatic decline in cyclin D1 levels during the preceding
S phase allows efficient DNA synthesis, and ensures that
proliferative conditions are conducive for continued
growth at the time of commitment for continuing prolif-
eration during G2 phase (Fig. 3). We find no evidence that
GSK3 is involved in regulating cyclin D1 expression or
intracellular localization in actively proliferating cells.
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